Hair analysis for beta-blockers and calcium-channel blockers by using liquid chromatography-tandem mass spectrometry as a tool for monitoring adherence to antihypertensive therapy.
Francesco TausRossella GottardoMarco BallotariChiara UtzeriFranco TagliaroPublished in: Drug testing and analysis (2022)
Adherence to therapy is the key to a successful therapeutic intervention, especially in cardiovascular diseases in which a lack of adherence may have serious consequences in terms morbidity and/or mortality. In this context, hair analysis can be an excellent tool to monitor adherence to therapy. Indeed, drugs present in blood are incorporated into the hair matrix, where drugs and metabolites can stay unaltered for a long time protected from metabolism and degradation. In the present study, a simple, specific, and sensitive ultra-high performance liquid-chromatography-tandem mass spectrometry (UHPLC-MS/MS) method set up to determine in human hair seven beta-blockers (viz., metoprolol, sotalol, labetalol, atenolol, nebivolol, bisoprolol, and nadolol) and two calcium-channel blockers (lercanidipine and amlodipine), which are widely prescribed to treat medium-to-severe hypertensive conditions. The optimized method was successfully validated in terms of accuracy, repeatability, reproducibility, matrix effect and extraction recovery. Moreover, the applicability of the method was evaluated by analyzing 34 real samples of hair obtained from patients under long-term therapy with calcium channel blockers and beta-blockers.
Keyphrases
- liquid chromatography tandem mass spectrometry
- ms ms
- angiotensin converting enzyme
- simultaneous determination
- solid phase extraction
- end stage renal disease
- blood pressure
- cardiovascular disease
- randomized controlled trial
- angiotensin ii
- endothelial cells
- chronic kidney disease
- stem cells
- high resolution
- peritoneal dialysis
- coronary artery disease
- patient reported outcomes
- high performance liquid chromatography
- cardiovascular risk factors
- drug induced
- smoking cessation
- induced pluripotent stem cells
- replacement therapy
- data analysis